Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

Gal-475 is under clinical development by Neurim Pharmaceuticals and currently in Phase I for Sleep Apnea. According to GlobalData, Phase I drugs for Sleep Apnea have a 96% phase transition success ...

The holiday season might be coming to a close — but the deals are still going strong. In fact, the new Apple Watch 10 is ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

Women with pregnancy-onset OSA had significantly higher nocturnal systolic BP and daytime diastolic BP, relative to those ...

The U.S. Food and Drug Administration (FDA) has approved Zepbound, a prescription weight-loss medication, as the first drug ...

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

Can exhaustion cause hallucinations? Discover the surprising effects of sleep deprivation on the mind and body. From impaired ...

This time last year, people were still bickering about whether Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound represented a shortcut to losing weight or a medical breakthrough. But with reams of ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

Postmenopausal sleep issues contribute to a sharp decline in sleep quality among older women, beginning at approximately 51 years of age.